Pancreatic Cancer Research

ResearcherUniversitätsmedizin GöttingenActive in the last 2 years

Michael B. Ghadimi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8208-1526; OpenAlex author ID A5005110488. Sources: OpenAlex.

Their work

Papers
33 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
182
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 3 papers · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 4 papers · 2024: 8 papers · 2025: 5 papers · 2026: 8 papers

Papers 33

  1. The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/mco2.70794↗
  2. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  3. Targeting Mutual Dependence of Phosphatidylinositol-3-Kinase α/δ and Small Ubiquitin-Like Modifier Signaling in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2025.08.018↗
  4. Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam. Co-author DOI 10.1158/2767-9764.crc-25-0670↗
  5. Spatially-resolved subtype progression reveals metabolic vulnerabilities in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12943-026-02628-3↗
  6. Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomi… First author DOI 10.1200/jco-25-03004↗
  7. Combined Preoperative Risk Score Including sCD40, Leukocytes, and BMI Predicts Pancreas-Specific Complications After Pancreatic Cancer Surgery. Co-author DOI 10.1245/s10434-026-19628-8↗
  8. ASO Visual Abstract: Combined Preoperative Risk Score Including sCD40, Leukocytes, and BMI Predicts Pancreas-Specific Complications After Pancreatic Cancer Sur… Co-author DOI 10.1245/s10434-026-19708-9↗
  9. KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. Co-author DOI 10.1002/1878-0261.13725↗
  10. TP53 missense-specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer. Co-author DOI 10.1126/sciadv.adu2339↗
  11. Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatm… Co-author DOI 10.1186/s12885-025-13573-7↗
  12. Perioperative outcomes in an age-adapted analysis of the German StuDoQ|Pancreas registry for PDAC. Co-author DOI 10.1186/s12893-024-02647-1↗
  13. Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO… First author DOI 10.1200/jco-24-01502↗
  14. A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction. Co-author DOI 10.1002/advs.202307695↗
  15. ELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer. Co-author DOI 10.1002/ijc.34960↗
  16. A retrospective, multicentric, nationwide analysis of the impact of splenectomy on survival of pancreatic cancer patients. Co-author DOI 10.1007/s00423-024-03570-y↗
  17. LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism. Co-author DOI 10.1093/carcin/bgae011↗
  18. MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK-ERK and AP-1 pathways. Co-author DOI 10.1093/carcin/bgae025↗
  19. ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. Co-author DOI 10.1093/carcin/bgae056↗
  20. Surgical Outcome After Distal Pancreatectomy With and Without Portomesenteric Venous Resection in Patients with Pancreatic Adenocarcinoma: A Transatlantic Eval… Co-author DOI 10.1245/s10434-024-15932-3↗
  21. ASO Author Reflections: Distal Pancreatectomy With and Without Portomesenteric Venous Resection for Pancreatic Adenocarcinoma: A Transatlantic Evaluation of Pa… Co-author DOI 10.1245/s10434-024-16021-1↗
  22. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… Co-author DOI 10.1016/j.annonc.2022.09.161↗
  23. SERPINB3-MYC axis induces the basal-like/squamous subtype and enhances disease progression in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2023.113434↗
  24. Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer. Co-author DOI 10.1038/s41698-023-00459-9↗
  25. Consensus Statement on the Use of Near-Infrared Fluorescence Imaging during Pancreatic Cancer Surgery Based on a Delphi Study: Surgeons' Perspectives on Curren… Co-author DOI 10.3390/cancers15030652↗
  26. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-… Co-author DOI 10.1007/s00066-020-01680-2↗
  27. CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic can… Co-author DOI 10.1016/j.ejca.2020.06.032↗
  28. CA19-9 for detecting recurrence of pancreatic cancer. Co-author DOI 10.1038/s41598-020-57930-x↗
  29. The impact of preoperative biliary stenting in pancreatic cancer: A case-matched study from the German nationwide pancreatic surgery registry (DGAV StuDoQ|Panc… Co-author DOI 10.1016/j.pan.2019.09.007↗
  30. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial. Co-author DOI 10.1186/s12885-019-6148-5↗
  31. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Co-author DOI 10.7150/thno.29247↗
  32. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Ra… Co-author DOI 10.1200/jco.2017.72.6463↗
  33. Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pa… Co-author DOI 10.1002/ijc.27736↗

Closest collaborators

The 25 strongest of 182 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Waldemar H. Uhl · 11 shared papers, 2019–2026 · strength 1.51
  2. Jochen Gaedcke · 10 shared papers, 2013–2025 · strength 1.44
  3. Elisabeth Heßmann · 7 shared papers, 2024–2026 · strength 1.32
  4. Günter Schneider · 6 shared papers, 2024–2026 · strength 1.11
  5. Azadeh Azizian · 6 shared papers, 2020–2024 · strength 1.01
  6. Volker Ellenrieder · 5 shared papers, 2024–2026 · strength 0.93
  7. Nader N Hanna · 6 shared papers, 2013–2024 · strength 0.93
  8. S. Perwez Hussain · 6 shared papers, 2013–2024 · strength 0.93
  9. Matthias Wirth · 5 shared papers, 2024–2026 · strength 0.92
  10. Dieter Saur · 5 shared papers, 2024–2026 · strength 0.92
  11. Carolin Schneider · 5 shared papers, 2024–2026 · strength 0.90
  12. Yuuki Ohara · 5 shared papers, 2023–2024 · strength 0.90
  13. Anke Reinacher‐Schick · 6 shared papers, 2019–2026 · strength 0.77
  14. Tobias Keck · 5 shared papers, 2019–2025 · strength 0.74
  15. Paloma Moreno · 4 shared papers, 2023–2024 · strength 0.72
  16. Helmut Oettle · 6 shared papers, 2017–2026 · strength 0.72
  17. Marian Grade · 4 shared papers, 2024–2026 · strength 0.71
  18. Maximilian Reichert · 4 shared papers, 2024–2026 · strength 0.71
  19. Lukas Krauß · 4 shared papers, 2024–2026 · strength 0.71
  20. Christian Schneeweis · 4 shared papers, 2024–2026 · strength 0.71
  21. Constanza Tapia Contreras · 4 shared papers, 2024–2026 · strength 0.71
  22. Uwe A. Wittel · 5 shared papers, 2019–2026 · strength 0.70
  23. David Digomann · 3 shared papers, 2023–2026 · strength 0.66
  24. Adrian M. Seifert · 3 shared papers, 2023–2026 · strength 0.66
  25. Lena Seifert · 3 shared papers, 2023–2026 · strength 0.66

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.